Advances in MM therapy have come about due to therapies that target vulnerabilities of the plasma cell such as high protein load (proteasome inhibitor (PI); bortezomib, ixazomib and carfilzomib), dependence on specific transcription factors such as IKZF1 and IKZF3 which are degraded by immunomodulatory drugs (IMiDs; thalidomide, lenalidomide, and pomalidomide), the susceptibility of B cells to glucocorticoids (Dexamethasone) and the presence of specific B cell markers that can serve as targets for monoclonal antibodies and CAR-T cells (BCMA). Here, IKZF1 is linked to Miyoshi myopathy.